APOEε2 is associated with milder clinical and pathological Alzheimer disease

Annals of Neurology

Volumn 77, Issue 6, 2015, Pages 917-929

  Serrano Pozo, Alberto ^a,b,c   Qian, Jing ^d   Monsell, Sarah E ^e   Betensky, Rebecca A ^b,f   Hyman, Bradley T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Massachusetts Alzheimer Disease Research Center   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 2; APOLIPOPROTEIN E EPSILON 3; APOLIPOPROTEIN E EPSILON 4; UNCLASSIFIED DRUG; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

AGED; ALLELE; ALZHEIMER DISEASE; ARTERIOSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CLINICAL DEMENTIA RATING SUM OF BOXES; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA ASSESSMENT; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENOTYPE; HIPPOCAMPAL SCLEROSIS; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; ONSET AGE; PRIORITY JOURNAL; SENILE PLAQUE; VASCULAR AMYLOIDOSIS; VERY ELDERLY; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; COHORT STUDIES; FEMALE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX;

EID: 84930014969     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24369     Document Type: Article

References (88)

1. Corder EH, Saunders AM, Strittmatter WJ, et al., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
2. Poirier J, Davignon J, Bouthillier D, et al., Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342: 697-699.
3. Rebeck GW, Reiter JS, Strickland DK, Hyman BT,. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993; 11: 575-580.
4. Saunders AM, Strittmatter WJ, Schmechel D, et al., Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
5. Benjamin R, Leake A, McArthur FK, et al., Protective effect of apoE epsilon 2 in Alzheimer's disease. Lancet 1994; 344: 473.
6. Corder EH, Saunders AM, Risch NJ, et al., Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7: 180-184.
7. Smith AD, Johnston C, Sim E, et al., Protective effect of apo epsilon 2 in Alzheimer's disease. Oxford Project to Investigate Memory and Ageing (OPTIMA). Lancet 1994; 344: 473-474.
8. Talbot C, Lendon C, Craddock N, et al., Protection against Alzheimer's disease with apoE epsilon 2. Lancet 1994; 343: 1432-1433.
9. West HL, Rebeck GW, Hyman BT,. Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. Neurosci Lett 1994; 175: 46-48.
10. Caselli RJ, Walker D, Sue L, et al., Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett 2010; 473: 168-171.
11. Gomez-Isla T, West HL, Rebeck GW, et al., Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996; 39: 62-70.
12. Hyman BT, West HL, Rebeck GW, et al., Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci U S A 1995; 92: 3586-3590.
13. McNamara MJ, Gomez-Isla T, Hyman BT,. Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch Neurol 1998; 55: 1001-1004.
14. Morris CM, Benjamin R, Leake A, et al., Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians. Neurosci Lett 1995; 201: 45-47.
15. Nagy Z, Esiri MM, Jobst KA, et al., The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 165-170.
16. Ohm TG, Scharnagl H, März W, Bohl J,. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol 1999; 98: 273-280.
17. Polvikoski T, Sulkava R, Haltia M, et al., Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995; 333: 1242-1247.
18. Schmechel DE, Saunders AM, Strittmatter WJ, et al., Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 9649-9653.
19. Tiraboschi P, Hansen LA, Masliah E, et al., Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004; 62: 1977-1983.
20. Yip AG, McKee AC, Green RC, et al., APOE, vascular pathology, and the AD brain. Neurology 2005; 65: 259-265.
21. Berg L, McKeel DW, Miller JP, et al., Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998; 55: 326-335.
22. Chalmers K, Wilcock GK, Love S,. APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol 2003; 29: 231-238.
23. Greenberg SM, Rebeck GW, Vonsattel JP, et al., Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995; 38: 254-259.
24. Olichney JM, Hansen LA, Hofstetter CR, et al., Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4. Arch Neurol 2000; 57: 869-874.
25. Premkumar DR, Cohen DL, Hedera P, et al., Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996; 148: 2083-2095.
26. Rannikmäe K, Kalaria RN, Greenberg SM, et al., APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis. J Neurol Neurosurg Psychiatry 2014; 85: 300-305.
27. Barthel H, Gertz H-J, Dresel S, et al., Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011; 10: 424-435.
28. Drzezga A, Grimmer T, Henriksen G, et al., Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009; 72: 1487-1494.
29. Johnson KA, Sperling RA, Gidicsin CM, et al., Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013; 9 (5 suppl): S72-S83.
30. Morris JC, Roe CM, Xiong C, et al., APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010; 67: 122-131.
31. Reiman EM, Chen K, Liu X, et al., Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106: 6820-6825.
32. Bu G,. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009; 10: 333-344.
33. Kim J, Basak JM, Holtzman DM,. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009; 63: 287-303.
34. Nagy Z, Esiri MM, Jobst KA, et al., Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995; 69: 757-761.
35. Bennett DA, Schneider JA, Wilson RS, et al., Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J Neurol Neurosurg Psychiatry 2005; 76: 1194-1199.
36. Mungas D, Tractenberg R, Schneider JA, et al., A 2-process model for neuropathology of Alzheimer's disease. Neurobiol Aging 2014; 35: 301-308.
37. Berlau DJ, Corrada MM, Robinson JL, et al., Neocortical β-amyloid area is associated with dementia and APOE in the oldest-old. Alzheimers Dement 2013; 9: 699-705.
38. Lippa CF, Smith TW, Saunders AM, et al., Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology 1997; 48: 515-519.
39. Beekly DL, Ramos EM, Lee WW, et al., The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord 2007; 21: 249-258.
40. Morris JC, Weintraub S, Chui HC, et al., The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006; 20: 210-216.
41. Weintraub S, Salmon D, Mercaldo N, et al., The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord 2009; 23: 91-101.
42. Morris JC,. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
43. Folstein MF, Folstein SE, McHugh PR,. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
44. Braak H, Braak E,. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
45. Braak H, Alafuzoff I, Arzberger T, et al., Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.
46. Mirra SS, Heyman A, McKeel D, et al., The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
47. Thal DR, Rüb U, Orantes M, Braak H,. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
48. Montine TJ, Phelps CH, Beach TG, et al., National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012; 123: 1-11.
49. Hyman BT, Phelps CH, Beach TG, et al., National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13.
50. Agresti A, Agresti A,. Categorical data analysis. Hoboken, NJ: John Wiley & Sons, 2002.
51. Yee TM,. The VGAM package for categorical data analysis. J Stat Softw 2010; 32: 1-34.
52. Serrano-Pozo A, Qiang J, Monsell SE, et al., Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol 2013; 72: 1182-1192.
53. Imai K, Keele L, Tingley D,. A general approach to causal mediation analysis. Psychol Methods 2010; 15: 309-334.
54. Imai K, Yamamoto T,. Identification and sensitivity analysis for multiple causal mechanisms: revisiting evidence from framing experiments. Polit Anal 2013; 21: 141-171.
55. Tingley D, Yamamoto T, Hirose K, et al., mediation: R package for causal mediation analysis. J Stat Softw 2014; 59: 1-38.
56. Brecht WJ, Harris FM, Chang S, et al., Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 2004; 24: 2527-2534.
57. Fleming LM, Weisgraber KH, Strittmatter WJ, et al., Differential binding of apolipoprotein E isoforms to tau and other cytoskeletal proteins. Exp Neurol 1996; 138: 252-260.
58. Huang DY, Weisgraber KH, Goedert M, et al., ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. Neurosci Lett 1995; 192: 209-212.
59. Huang Y, Liu XQ, Wyss-Coray T, et al., Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A 2001; 98: 8838-8843.
60. Strittmatter WJ, Saunders AM, Goedert M, et al., Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A 1994; 91: 11183-11186.
61. Hudry E, Dashkoff J, Roe AD, et al., Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 2013; 5: 212ra161.
62. Pooler AM, Polydoro M, Wegmann SK, et al., Tau-amyloid interactions in the rTgTauEC model of early Alzheimer's disease suggest amyloid-induced disruption of axonal projections and exacerbated axonal pathology. J Comp Neurol 2013; 521: 4236-4248.
63. Bennett DA, Schneider JA, Wilson RS, et al., Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004; 61: 378-384.
64. Hashimoto T, Serrano-Pozo A, Hori Y, et al., Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J Neurosci 2012; 32: 15181-15192.
65. Koffie RM, Hashimoto T, Tai H-C, et al., Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain J Neurol 2012; 135 (pt 7): 2155-2168.
66. Castellano JM, Kim J, Stewart FR, et al., Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 2011; 3: 89ra57.
67. Götz J, Chen F, van Dorpe J, Nitsch RM,. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293: 1491-1495.
68. Lewis J, Dickson DW, Lin WL, et al., Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-1491.
69. Pooler AM, Polydoro M, Maury EA, et al., Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. Acta Neuropathol Commun 2015; 3: 14. doi: 10.1186/s40478-015-0199-x
70. Greenberg SM, Vonsattel JP, Segal AZ, et al., Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 1998; 50: 961-965.
71. Cosentino S, Scarmeas N, Helzner E, et al., APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 2008; 70: 1842-1849.
72. Craft S, Teri L, Edland SD, et al., Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 1998; 51: 149-153.
73. Wilson RS, Schneider JA, Barnes LL, et al., The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol 2002; 59: 1154-1160.
74. Bracco L, Piccini C, Baccini M, et al., Pattern and progression of cognitive decline in Alzheimer's disease: role of premorbid intelligence and ApoE genotype. Dement Geriatr Cogn Disord 2007; 24: 483-491.
75. Dal Forno G, Rasmusson DX, Brandt J, et al., Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol 1996; 53: 345-350.
76. Growdon JH, Locascio JJ, Corkin S, et al., Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996; 47: 444-448.
77. Kleiman T, Zdanys K, Black B, et al., Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord 2006; 22: 73-82.
78. Kurz A, Egensperger R, Haupt M, et al., Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 1996; 47: 440-443.
79. Murphy GM Jr, Taylor J, Kraemer HC, et al., No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. Am J Psychiatry 1997; 154: 603-608.
80. Norrman J, Brookes AJ, Yates C, St Clair D,. Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease. Br J Psychiatry 1995; 167: 533-536.
81. Tschanz JT, Corcoran CD, Schwartz S, et al., Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry 2011; 19: 532-542.
82. Hoyt BD, Massman PJ, Schatschneider C, et al., Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol 2005; 62: 454-459.
83. Stern Y, Brandt J, Albert M, et al., The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997; 41: 615-620.
84. Van der Vlies AE, Koedam ELGE, Pijnenburg YAL, et al., Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset. Psychol Med 2009; 39: 1907-1911.
85. Bonner-Jackson A, Okonkwo O, Tremont G, Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E 2 and functional decline in amnestic mild cognitive impairment and Alzheimer disease. Am J Geriatr Psychiatry 2012; 20: 584-593.
86. Wilson RS, Bienias JL, Berry-Kravis E, et al., The apolipoprotein E epsilon 2 allele and decline in episodic memory. J Neurol Neurosurg Psychiatry 2002; 73: 672-677.
87. Beach TG, Monsell SE, Phillips LE, Kukull W,. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012; 71: 266-273.
88. Serrano-Pozo A, Qian J, Monsell SE, et al., Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol 2014; 75: 597-601.